Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug,

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury and previous problems with pill versions.